Meeting
2019 ASCO Annual Meeting
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
Authors
David A. Reardon
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
David A. Reardon , Thomas Joseph Kaley , Jorg Dietrich , Jennifer Leigh Clarke , Gavin Dunn , Michael Lim , Timothy Francis Cloughesy , Hui Kong Gan , Andrew J. Park , Paul Schwarzenberger , Toni Ricciardi , Mary J. Macri , Aileen Ryan , Ralph Rudolph Venhaus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02336165
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2032)
DOI
10.1200/JCO.2019.37.15_suppl.2032
Abstract #
2032
Poster Bd #
221
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
First Author: David A. Reardon
Poster
2015 ASCO Annual Meeting
Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).
First Author: David A. Reardon
Poster
2023 ASCO Annual Meeting
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
First Author: William Joseph Chapin
Poster
2021 ASCO Annual Meeting
Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.
First Author: Jian Li Campian